Mandate

Vinge advises Tele2 in the merger with Com Hem

Tele2 AB (publ) and Com Hem Holding AB (publ) announced on 10 January 2018 that they have agreed on a combination through a statutory merger in accordance with the Swedish Companies Act.

The combined company will be a leading integrated connectivity provider by combining an award-winning mobile network with the fastest national fixed network and the widest range of content in the market. The combination is conditional upon, inter alia, approval from the relevant competition authorities and approval of the merger from the shareholders in Tele2 and Com Hem. The merger is currently expected to be completed in the second half of 2018.

Vinge’s team primarily consists of Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Amanda Knutsson and Annika Nyberg Ekenberg (capital markets), Marcus Glader, Johan Karlsson, Emma Johansson, Grant McKelvey and Sebastian Örndahl (competition and regulatory), Louise Brorsson Salomon, Helena Håkansson and Lionardo Ojeda (financing) as well as Fredrik Dahl and Fredrik Gustafsson (employment).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026